106 related articles for article (PubMed ID: 322260)
1. Human leukocyte migration inhibitory factor (LIF). II. Partial biochemical characterization of the substrate specificities for this lymphokine.
Bendtzen K
Scand J Immunol; 1977; 6(1-2):133-40. PubMed ID: 322260
[TBL] [Abstract][Full Text] [Related]
2. Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors.
Bendtzen K
Scand J Immunol; 1977; 6(1-2):125-31. PubMed ID: 322257
[TBL] [Abstract][Full Text] [Related]
3. Human leukocyte migration inhibitory factor (LIF). IV. 3',5'-cGMP protects LIF against inactivation by the esterase inhibitor phenylmethylsulfonyl fluoride.
Bendtzen K
Scand J Immunol; 1977; 6(12):1357-61. PubMed ID: 203999
[TBL] [Abstract][Full Text] [Related]
4. Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors.
Bendtzen K
Scand J Immunol; 1977; 6(1-2):126-31. PubMed ID: 322258
[TBL] [Abstract][Full Text] [Related]
5. Human leukocyte migration inhibitory factor (LIF) III. Further investigations on the serine protease nature of this lymphokine and its preference for arginine amides.
Bendtzen K
Scand J Immunol; 1977; 6(10):1055-62. PubMed ID: 335493
[TBL] [Abstract][Full Text] [Related]
6. Substrate specificity of the human lymphokine leucocyte migration-inhibitory factor (LIF): radioenzymic assay and inhibition by cGMP.
Bendtzen K
Scand J Immunol; 1979; 10(1):61-7. PubMed ID: 224450
[TBL] [Abstract][Full Text] [Related]
7. Determination of the human lymphokine leukocyte migration inhibitory factor (LIF) by a sensitive radioenzymatic assay. Inhibitory effect of cGMP on the esterolytic activity of highly purified LIF.
Bendtzen K
J Clin Lab Immunol; 1979 Apr; 2(1):37-43. PubMed ID: 95804
[TBL] [Abstract][Full Text] [Related]
8. Some physicochemical properties of human leucocyte migration inhibitory factor (LIF).
Bendtzen K
Acta Pathol Microbiol Scand C; 1976 Dec; 84C(6):471-6. PubMed ID: 11637
[TBL] [Abstract][Full Text] [Related]
9. Use of benzoyl-L-phenylalanyl-L-valyl-L-arginine (3H) methyl ester as a sensitive and selective substrate for the human lymphokine, leukocyte migration inhibitory factor (LIF).
Bendtzen K; Rocklin RE
J Immunol; 1980 Oct; 125(4):1775-81. PubMed ID: 6251137
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of the human lymphokine leukocyte migration inhibitory factor (LIF): role of cGMP as a specific inhibitor of the LIF esterase activity.
Bendtzen K
Adv Exp Med Biol; 1979; 114():485-90. PubMed ID: 223417
[No Abstract] [Full Text] [Related]
11. Evidence that human leukocyte inhibitory factor (LIF) is an esterase.
Rocklin RE; Rosenthal AS
J Immunol; 1977 Jul; 119(1):249-52. PubMed ID: 326958
[No Abstract] [Full Text] [Related]
12. Human leucocyte migration inhibitory factor (LIF). V. Specific regulation of the lymphokine serine protease activity by 3',5'-cGMP and, possibly, 2',3'-cCMP.
Bendtzen K
Scand J Immunol; 1978; 8(1):53-61. PubMed ID: 212822
[TBL] [Abstract][Full Text] [Related]
13. Differential effect of the serine protease inhibitor phenyl methyl sulfonyl fluoride on cytochemically detectable esterases in human leucocytes and platelets.
Dufer J; Trentesaux C; Desplaces A
Scand J Haematol; 1984 Jan; 32(1):25-32. PubMed ID: 6364322
[TBL] [Abstract][Full Text] [Related]
14. Kinetic interactions of a neuropathy potentiator (phenylmethylsulfonyl fluoride) with the neuropathy target esterase and other membrane bound esterases.
Mangas I; Vilanova E; Estévez J
Arch Toxicol; 2014 Feb; 88(2):355-66. PubMed ID: 24071788
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and functional properties of serine esterases in acidic cytoplasmic granules of cytotoxic T lymphocytes.
Henkart PA; Berrebi GA; Takayama H; Munger WE; Sitkovsky MV
J Immunol; 1987 Oct; 139(7):2398-405. PubMed ID: 3498759
[TBL] [Abstract][Full Text] [Related]
16. Esterases of the polymorphonuclear leukocyte capable of hydrolyzing acetyl DL-phenyl-alanine beta-naphthyl ester. Relationship to the activatable esterase of chemotaxis.
Becker EL; Ward PA
J Exp Med; 1969 Mar; 129(3):569-84. PubMed ID: 5812915
[TBL] [Abstract][Full Text] [Related]
17. Human leukocyte inhibitory factor (LIF): a lymphocyte mediator with esteratic properties.
Rocklin R
Fed Proc; 1978 Nov; 37(13):2743-7. PubMed ID: 710595
[TBL] [Abstract][Full Text] [Related]
18. Increased polymorphonuclear leukocyte cGMP levels induced by the human lympholine, leukocyte migration inhibitory factor (LIF).
Bendtzen K; Klysner R
Immunopharmacology; 1979 Jul; 1(4):323-30. PubMed ID: 233586
[TBL] [Abstract][Full Text] [Related]
19. Production of leucocyte inhibitory factor (LIF) and macrophage inhibitory factor (MIF) by PHA-stimulated lymphocytes.
Ruthlomnitzer ; Rabson AR; Koornhof HJ
Clin Exp Immunol; 1975 Dec; 22(3):522-7. PubMed ID: 773578
[TBL] [Abstract][Full Text] [Related]
20. Amplification of the activity of human leukocyte inhibitory factor (LIF) by the generation of a low molecular weight inhibitor of PMN leukocyte chemotaxis.
Goetzl EJ; Rocklin RE
J Immunol; 1978 Sep; 121(3):891-6. PubMed ID: 690441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
